AzTrials
AzTrials

Type 2 DiabetesNCT02883127

Motivational Interviewing With Focus on Diet and Weight Gain in Pregnant Women With Type 2 Diabetes

An observational study of Type 2 Diabetes and Pregnancy, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary goal of this case control study is to investigate the effect of implementation of motivational interviewing with focus on diet and weight gain in addition to the routine treatment on prevention of excessive gestational weight gain and fetal growth in pregnant women with type 2 diabetes. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Type 2 Diabetes, Pregnancy
What is being tested?
Motivational interviewing
How many people
189 participants
Where
1 siteDenmark
Study dates
1 Aug 2015to 1 Oct 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: A cohorte of unselected consecutive pregnant women with type 2 diabetes. The inclusion period of the study group is planned from August 2015 to August 2017. The control group consists of the cohort of women referred for pregnancy care in the period of August 2013 to August 2015 fulfilling the same inclusion criteria and followed the same routine care as the study group. Each cohort is expected to include 150 women.

Who may be able to join

  • All pregnant women with type 2 diabetes and older than 18 years referred to Center for Pregnant Women with Diabetes, Rigshospitalet or Department of Obstetrics and Endocrinology, Odense University Hospital with a live singleton pregnancy will be included in the study group. All pregnant women with type 2 diabetes in the period August 2013 - August 2015 who received routine care only at the same centers will be included in the control group.´
  • Referral before 20 gestational weeks. Women with newly diagnosed type 2 diabetes before week 20 may be included (HbA1c ≥ 48 mmol/mol).
  • Able to read and understand the patient information sheet and to converse with the lifestyle coach in Danish.

Who cannot join

  • Previous bariatric surgery i.e. ether previous gastric bypass or gastric banding operation.
  • Women diagnosed with severe diseases which possibly could bias the weight gain or pregnancy outcome on the decision of the principal investigators.

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Center for Pregnant Women with Diabetes

    Copenhagen, Østerbro, 2100

Other trials in Denmark

About this study

Official title: The Effect of Motivational Interviewing With Focus on Diet and Weight Gain on Prevention of Excessive Fetal Growth in Pregnant Women With Type 2 Diabetes

The primary goal of this case control study is to investigate the effect of implementation of motivational interviewing with focus on diet and weight gain in addition to the routine treatment on prevention of excessive gestational weight gain and fetal growth in pregnant women with type 2 diabetes.

Design: Prospective cohort study where an unselected cohort of all pregnant women with type 2 diabetes are offered intervention with motivational interviewing in addition to routine treatment in the period 2015-2017. For comparison a historical cohort (2013-2015) treated with routine treatment only will be studied. With an inclusion period of 2 years, each cohort is expected to include 150 participants. The women in the study group will receive one-to-one coaching based on the principles of motivational interviewing, every second week throughout the pregnancy. Both cohorts receive the same routine care for pregnant women with type 2 diabetes. An appropriate GWG is targeted. Primary outcome measures are maternal gestational weight gain and the infants Large for Gestational Age.

Read the detailed description

The Aims: First, to investigate the effect of implementation of motivational interviewing focusing on diet adherence in addition to routine treatment on prevention of excessive gestational weight gain and fetal overgrowth.

Secondly, to investigate the impact of quantity and quality of carbohydrate consumption on HbA1c, gestational weight gain and fetal overgrowth.

Thirdly, to explore the occurence of anxiety and depression and relation to pregnancy outcome.

Study design:

The study group will get a life-style intervention with motivational interviewing focusing on following the recommended diabetes diet and gestational weight gain recommendations in addition to routine care - as described below.

The control group was given the same routine care with the same treatment goals, but without motivational interviewing.

Lifestyle intervention with motivational interviewing:

The individual sessions with a lifestyle coach will be scheduled for each participant and tailored to suite in the routine clinical visits of the patients. The women will follow routine visits and the lifestyle coaching is sought implemented in the routine clinical setting without excess use of one-to one contacts with a caregiver.

The lifestyle coaching is built op on principles of patient empowerment and cognitive behavioral techniques, inspired by motivational interviewing. In the program, one-to-one contact will be offered. The aim is to provide a one-to-one contact every second week of approximately 10 minutes duration. Women living in a long distance form the clinic may convert some of the one-to-one contact to telephone calls. The timing of these contacts and the time between these contacts are dependent on the preference of the participant and the availability of the lifestyle coach in order to deliver the intervention with the most appropriate timing and to optimize changes of the uptake of behavior change. However it is stressed that the one-to-one coaching sessions should be initiated within 14 days after first visit at the clinic and occurs before gestational week 20. The first phase of behavioral change is centered on intention formation (motivation). Current behavior will be assessed and motivation for change will be established. When the woman is ready to make the change, personal goals will be set. An action plan for improving dietary behavior will be made during the first session and evaluated in subsequent sessions. The following dietary objectives will be set for each participant to achieve or to maintain:

  1. Watch portion size - to be conscious about the amount of carbohydrates in each meal.
  2. Eat mainly carbohydrates of low glycaemic index (i.e. vegetables and rye bread).
  3. Reduce the intake of carbohydrate of high glycaemic index (i.e. white bread, cakes, candy, snacks, chips, ice cream)
  4. Watch daily weight changes - aim for the recommended weekly changes.

The lifestyle coaches have received a special training program containing motivational interviewing techniques. The doctors, dieticians and nurses taking care of the routine clinical visits will continue their usual care without focus on motivational interviewing. The lifestyle coaches are educated midwives, nurses or doctors and will also be trained in performing the routine clinical diabetes visits at the same visit as the coaching visit if possible, in order avoid excess expense of one-to-one contacts with a caregiver.

In addition to the motivational intervention the women are given unchanged routine care.

The routine care includes the following goals for both groups:

The aim for glycaemic control is according to the Danish National guidelines in essence aiming for preprandial plasma glucose values between 4-6 mmol/l and postprandial values between 4 and 8 mmol/l. Due to changes in measuring HbA1c in mmol/mol the goal for HbA1c is slightly modified to below 40 mmol/mol during pregnancy.

The goals for gestational weight gain follow the Copenhagen guidelines for pregnant diabetic women:

Pre-pregnancy BMI <25 kg/m2: 10-15 kg in total with 100 g/week in first half of pregnancy and thereafter 400 g/week.

Pre-pregnancy BMI: 25-30 kg/m2: 5-8 kg in total with 100 gram per week in first half of pregnancy and thereafter 300g/week.

Pre-pregnancy BMI >30 kg/m2: 5 kg in total with 0 g/week in first half of pregnancy and thereafter 200 g/week.

Recommendations regarding diet and physical activity - in brief

The women will get a one-to-one consultation with certified dietitian once during pregnancy. The women will get information about recommended diabetes diet, education in carbohydrate counting and how to read a food label. Information about dietary apps is given to aid learning. The goals are as follows: A) Adequate nutrient intake to support a healthy pregnancy. B) Adequate but not excessive gestational weight gain within the Copenhagen guidelines for pregnant diabetic women according to pre-pregnancy BMI as stated above. C) Eating a total of approximately 175 grams of carbohydrate daily which is regarded to correspond to around150 g of the main sources of carbohydrates as bread, potatoes, rise, pasta, fruits, and dairy products. D) Diet mainly containing low GI carbohydrates. E) Aim for approximately 20-40-40 grams of carbohydrates at each main meal and 10-20 grams at 2-3 snacks daily from the main sources of carbohydrates. F) Consistent timing of three meals and 2-4 snacks daily.

Women without contraindications will be encouraged to be physical active for at least 30 min/day: mainly walking, cycling or swimming.

Procedure and data collection:

Clinical assessments will be made by a member of the research team at three time points: at baseline, 20-24 weeks and 35-37 weeks of gestation.

At first visit the following will be noted: the women´s self-reported weight before pregnancy. Height, current weight, waist, neck and ankle circumference and subcutaneous skinfolds will be measured. Consultations blood pressure but also a home blood pressure monitoring for 3 days will be registered. HbA1c concentration and plasma lipids (triglycerides, free fatty acids, total cholesterol, HDL cholesterol, LDL cholesterol) will be measured the same day. A dipstick of sterile urine will be screened for proteinuria/ketonuria. All medications including vitamins and total daily dose of insulin will be noted together with diabetes related complications (nephropathy or retinopathy). An ophthalmologist evaluates the presence or absence of diabetic retinopathy at first visit. Occurrence of mild and severe hypoglycaemia will be reported as well as the degree of nausea and vomiting. Women will be asked into the number of episodes of symptomatic mild hypoglycaemia the last week and in case of severe hypoglycaemia, details about the event will be documented in a structured way.

The women´s age, duration of diabetes, gestational age at first visit, parity, marital status, ethnicity, smoking, alcohol, sleeping pattern and social status (degree of education as well as current employment and shift work) will be noted.

The women will record 3 days of food diary with focus on content of carbohydrate from the main carbohydrate sources. These diaries will be used to evaluate the amount of carbohydrates and the amount of high/low glycemic index food with focus on the average daily total carbohydrate intake as well as the day-to-day variation. The degrees of leisure time physical activity will be sought evaluated by pregnancy physical activity questionnaire (PPAQ). Besides this, the women will complete a 6 item food frequency list, a Hospital Anxiety and Depression Scale (HADS) and a EuroQol-5D (EQ-5D).

At each clinical visit current weight and consultations blood pressure will be registered. HbA1c will be measured and a dipstick of sterile urine screened for ketone bodies and protein. All medications incl. total daily insulin dose will be noted together with information about the number of mild hypoglycaemic episodes the past week.

Additionally at study visits (20-24 weeks and 35-37 weeks) the women will complete a food diary for 3 days, 6 item food frequency list, PPAQ, HADS and EQ-5D. Information about smoking and sleeping patterns, nausea and vomiting will be noted. Bodyweight and waist, neck and ankle circumference and subcutaneous skinfolds will be measured. Consultations blood pressure as well as home blood pressure monitoring will be registered, presence of severe hypoglycaemia within the last year will be noted and detailed information about the episodes collected.

One year postpartum, the women will be contacted by telephone and asked for their current weight and in which degree the lifestyle-changes initiated during pregnancy are still followed according to their own judgment (licker scale). Information about duration of exclusive and total breastfeeding will be registered. Regarding the child, actual health, current weight as well as hospital admissions and presence of malformations will be obtained.

Being tested
Motivational interviewing
Keywords
Motivational Interviewing, Diet, Carbohydrates, Psychosocial factors
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Motivational interviewingBehavioural

    The aim is to provide a one-to-one contact every second week of approximately 10 minutes duration. An action plan for improving dietary behavior will be made during the first session and evaluated in subsequent sessions. The following dietary objectives will be set for each participant to achieve or to maintain:

    1. Watch portion size - to be conscious about the amount of carbohydrates in each meal.
    2. Eat mainly carbohydrates of low glycaemic index.
    3. Reduce the intake of carbohydrate of high glycaemic index.
    4. Watch daily weight changes - aim for the recommended weekly changes.

    In addition to the motivational intervention the women are given unchanged routine care.

Study groups in NCT02883127
Study groupRoleWhat they receive
The study groupReceives lifestyle intervention with motivational interviewing focusing on following the recommended diabetes diet and gestational weight gain recommendations in addition to routine care
Receives: Behavioral: Motivational interviewing
The control groupWas given the same routine care with the same treatment goals, but without motivational interviewing.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gestational weight gain

    The difference between weight measured at gestational week 35-37 and weight from preconception (self-reported) or if not available, at first pregnancy visit within first trimester.

    Measured: 2 years and 9 months

  2. Large for gestational age

    Birth weight ≥ 90th percentile, adjusted for gestational age and sex. Z-score ≥1.28.

    Measured: 2 years and 9 months

  3. HbA1c

    noted 3 times during pregnancy

    Measured: 2 years and 9 months

Secondary outcomes (38)
  1. Pre-eclampsia:

    De novo hypertension >140/90 mmHg after 20 weeks and the coexistence of one or more of the following new onset conditions:

    1. Proteinuria (spot urine protein/creatinine ratio ≥ 30 mg/mmol (0.3 mg/mg) or ≥ 300 mg/day or at least 1 g/L ('2+') on dipstick testing or albumin excretion (UAE) ≥ 190 mg/day or Albumin Creatine Ratio (UACR) ≥ 190 mg/g creatinine).
    2. Other maternal organ dysfunction:
    • renal insufficiency (creatinine ≥90 umol/L)
    • liver involvement (elevated transaminases; at least twice upper limit of normal and right upper quadrant or epigastric abdominal pain
    • Neurological complications (including eclampsia, altered mental status, blindness, stroke, hyperreflexia when accompanied by clonus, severe headaches when accompanied by hyperreflexia and persistent visual scotomata)
    • Haematological complications (thrombocytopenia: platelet count <150,000/dl, disseminated intravascular coagulation and haemolysis)
    1. Uteroplacental dysfunction and fetal growth restriction I

    Measured: 2 years and 9 months

  2. Preterm delivery

    Birth before 37 completed gestational weeks (259 days).

    Measured: 2 years and 9 months

  3. Caesarean section:

    • Emergency: The procedure is made within 8 hours after clinical decision.
    • Elective: Planned C-section.

    Measured: 2 years and 9 months

  4. Duration from induction of labor to delivery

    The time in hours from onset of intervention (example Misoprostol, Cervical Ripening Balloon, amniotomy) to delivery.

    Measured: 2 years and 9 months

  5. Duration of active labor

    Regular labor with contractions ≤ 5 minutes interval and orificium is ≥ 4 cm dilated without persistant collum. The appraisal will be made by local midwives.

    Measured: 2 years and 9 months

  6. Shoulder dystocia

    Shoulder dystocia is a situation when the fetus's shoulders cannot pass below the mother's pubic symphysis after delivery of the head and specific obstetric maneuvers, usually Rubin´s or/and Wood´s maneuvers, are necessary to deliver the baby. Presence of fetal asphyxia, nerve lesions and fractures will be noted.

    Measured: 2 years and 9 months

  7. Degree of rupture

    1. degree: laceration is limited to the fourchette and superficial perineal skin or vaginal mucosa.
    2. degree: laceration extends to perineal muscles and fascia.
    3. degree: laceration extends to the anal sphincter.
    4. degree: laceration extends to the rectal mucosa.

    Measured: 2 years and 9 months

  8. Birth weight z-score

    Number of standard deviations from the mean of a Nordic population, adjusted for gestational age and sex.

    Measured: 2 years and 9 months

  9. Small for Gestational Age (SGA)

    Birth weight ≤ 10th percentile, adjusted for gestational age and sex. Z-score ≤ 1.28.

    Measured: 2 years and 9 months

  10. Ponderal index

    Weight divided by the third power of body length.

    Measured: 2 years and 9 months

  11. International neonatal hypoglycemia:

    Neonatal hypoglycemia defined as a plasma glucose value below 2.2 mmol/L, measured within 4 hours of life.

    Measured: 2 years and 9 months

  12. Danish Neonatal hypoglycemia

    Neonatal hypoglycemia defined as a plasma glucose value below 2.5 mmol/L, measured within 4 hours of life.

    Measured: 2 years and 9 months

  13. Jaundice

    Need for phototherapy or exchange transfusion

    Measured: 2 years and 9 months

  14. Transient tachypnea of the newborn (TTN)

    A need for Continuous Positive Airway Pressure (CPAP) for more than 60 minutes.

    Measured: 2 years and 9 months

  15. Major congenital malformations

    Those leading to death, causing a substantial future handicap or requiring surgery.

    Measured: 3 years and 9 months

  16. Perinatal mortality

    Perinatal death includes infant deaths that occur at less than 28 days of age and fetal deaths with a stated or presumed period of gestation of 20 weeks or more.

    Measured: 2 years and 9 months

  17. Perinatal morbidity

    The occurrence of at least one of the following complications: neonatal hypoglycemia, jaundice, TTN, congenital malformations, perinatal mortality or admission to neonatal special care unit (NSCU).

    Measured: 2 years and 9 months

  18. Apgar score

    The examination immediately after birth on five criteria on a three point scale (0,1 and 2), with a maximum points of 10 after 5 minutes.

    Measured: 2 years and 9 months

  19. Body mass index (BMI)

    • Underweight: < 18.5 kg/m2
    • Normal weight: 18.5-24.9 kg/m2
    • Overweight: 25.0-29.9 kg/m2
    • Obese: ≥ 30.0 kg/m2

    Measured: 2 years

  20. Hypoglycaemia

    • Mild: Events with symptoms familiar to the patient as hypoglycemia and managed by the patient.
    • Severe: Events with symptoms of hypoglycemia requiring help from another person to actively administer oral carbohydrate or injection of glucagon or glucose in order to restore the blood glucose level.

    Measured: 2 years

  21. Kidney involvement

    Microalbuminuria or diabetic nephropathy.

    Measured: 2 years

  22. Diabetic nephropathy

    U-albumine >300 mg/day or ACR, >300 mg/g of creatinine or >34 mg/mmol of creatinine

    Measured: 2 years

  23. Microalbuminuria

    30-300 mg/day albumin or ACR, 30-300 mg/g of creatinine or 3.4-34 mg/mmol of creatinine.

    Measured: 2 years

  24. Diabetic retinopathy

    Presence of any diabetic retinopathy at first visit.

    Measured: 2 years

  25. Ethnicity

    -Nordic Caucasian: When pregnant woman originates from Northern Europe.

    Measured: 2 years

  26. Maternal waist circumference

    measured at the level midway between the lowest ribcage and the iliac crest

    Measured: 2 years

  27. Maternal neck circumference

    Measured between midcervical spine and mid-anterio neck

    Measured: 2 years

  28. Maternal ankle circumference

    measured 5 cm above the malleolus

    Measured: 2 years

  29. Infants weight, length, and head circumference

    Measured: 2 years and 9 months

  30. Infants abdominal circumference, upper- and lower arm and upper- and lower leg circumference

    Measured: 2 years and 9 months

  31. Infants skin fold measurements of triceps, quadriceps, subscapular and suprailiac region

    Measured: 2 years and 9 months

  32. Maternal lipid profile at first visit

    Measured: 2 years

  33. Cord blood pH

    Measured: 2 years and 9 months

  34. Post-partum weight retention

    Measured: 3 years and 9 months

  35. Baby´s weight at 1 year

    Measured: 3 years and 9 months

  36. Baby´s morbidity the first year

    Measured: 3 years and 9 months

  37. Maternal health during pregnancy

    HADS questionnaire

    Measured: 2 years

  38. Maternal after measurement of subcutaneous skin folds (biceps, triceps, suprailiac and subscapular).

    Measured with a Harpenden caliper according to the method described by Durnin and Womersly

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Aug 2016 (estimated)
  2. Study start1 Aug 2015
  3. Primary completion28 Feb 2018
  4. Study completion1 Oct 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
189 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02883127
Sponsor's protocol ID
H-15009413
Status last verified
May 2021
First submitted
25 Aug 2016
Last updated
5 May 2021
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided

Publications

  • Asbjornsdottir B, Vestgaard M, Do NC, Ringholm L, Andersen LLT, Jensen DM, Damm P, Mathiesen ER. Prevalence of anxiety and depression symptoms in pregnant women with type 2 diabetes and the impact on glycaemic control. Diabet Med. 2021 Mar;38(3):e14506. doi: 10.1111/dme.14506. Epub 2021 Jan 8.

    PubMed 33368557
  • Asbjornsdottir B, Vestgaard M, Ringholm L, Andersen LLT, Jensen DM, Damm P, Mathiesen ER. Effect of motivational interviewing on gestational weight gain and fetal growth in pregnant women with type 2 diabetes. BMJ Open Diabetes Res Care. 2019 Nov 7;7(1):e000733. doi: 10.1136/bmjdrc-2019-000733. eCollection 2019.

    PubMed 31798895

Questions about this trial

What is this clinical trial studying?

An observational study of Type 2 Diabetes and Pregnancy, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 May 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gestational weight gain (time frame: 2 years and 9 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02883127, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in